Li Hu
Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Single-Cell Immune Signature and Response to Neoadjuvant Chemotherapy in BRCA1/2-Mutated Breast Cancer.
Journal: JCO precision oncology
Published: November 06, 2025
Clinical Impact and Genomic Features of Human Epidermal Growth Factor Receptor 2-Low Tumors in BRCA1/2-Mutated Triple-Negative Breast Cancer.
Journal: JCO precision oncology
Published: March 26, 2025
Potential candidates for adjuvant olaparib treatment in operable breast cancer patients with germline BRCA1/2 pathogenic variants after neoadjuvant chemotherapy.
Journal: Breast cancer research and treatment
Published: July 03, 2024
Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants.
Journal: Breast cancer research and treatment
Published: January 08, 2024
Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Journal: International journal of cancer
Published: November 30, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026